Lonza Group AG LONN:SIX; LO3:FSE; LZAGF:OTCPK

Notable Quotes

"DMPI's VAL-083 is a first-in-class small-molecule chemotherapeutic." (4/17/14) DelMar Pharmaceuticals Inc. - The Life Sciences Report Interview with Grant Zeng More�>

"There is great potential for NEO to grow in the future." (4/17/14) NeoGenomics Laboratories - The Life Sciences Report Interview with Grant Zeng More�>

"SNGX has a very diversified pipeline under development; its Phase 2 trial for SGX924 is going very well." (4/17/14) Soligenix Inc. - The Life Sciences Report Interview with Grant Zeng More�>

"RXII has some very important valuation-driving events in progress." (4/10/14) RXi Pharmaceuticals Corp. - The Life Sciences Report Interview with Keith Markey More�>

"ARNI's chairman is one of the best in the world in the urology field, and the company's consortium of investors has given us a lot of validation." (4/3/14) Arno Therapeutics Inc. - The Life Sciences Report Interview with Ran Nussbaum More�>

Companies

Lonza Group AG

TICKER: LONN:SIX; LO3:FSE; LZAGF:OTCPK

Would you like more information on this company?

First Name *

Last Name

Email *

Phone

* Required

In addition, I would like to receive The Life Sciences Report Newsletter

Fact sheets, annual reports, webinars, CEO interviews and more, may be available for this company. Fill out this form and your contact information will be shared with this company to provide you with additional information.